Bank Of America Corp Avadel Pharmaceuticals PLC Transaction History

Bank Of America Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$12.55 - $17.22 $12,349 - $16,944	984 Added 2.85%	35,475 $599,000
Q4 2023 Feb 14, 2024	SELL	$9.64 - $14.59 $78,951 - $119,492	-8,190 Reduced 19.19%	34,491 $487,000
Q2 2023 Aug 14, 2023	SELL	$8.48 - $16.48 $5.51 Million - $10.7 Million	-649,545 Reduced 93.83%	42,681 $703,000
Q1 2023 May 12, 2023	BUY	$6.41 - $9.95 $3.76 Million - $5.83 Million	586,247 Added 553.17%	692,226 $6.34 Million
Q4 2022 Feb 10, 2023	BUY	$5.02 - $10.0 $179,982 - $358,530	35,853 Added 51.13%	105,979 $758,000
Q3 2022 Nov 14, 2022	SELL	$2.57 - $7.31 $10,932 - $31,096	-4,254 Reduced 5.72%	70,126 $351,000
Q2 2022 Aug 12, 2022	SELL	$1.07 - $6.95 $174,357 - $1.13 Million	-162,951 Reduced 68.66%	74,380 $181,000
Q1 2022 May 16, 2022	BUY	$5.46 - $8.29 $928,942 - $1.41 Million	170,136 Added 253.2%	237,331 $1.62 Million
Q4 2021 Feb 08, 2022	BUY	$7.34 - $11.18 $289,173 - $440,458	39,397 Added 141.73%	67,195 $542,000
Q3 2021 Nov 15, 2021	SELL	$6.49 - $9.91 $181,979 - $277,876	-28,040 Reduced 50.22%	27,798 $273,000
Q2 2021 Sep 13, 2021	BUY	$6.73 - $9.05 $375,789 - $505,333	55,838 New	55,838 $376,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.